SELLAS Life Sciences Group, Inc. (SLS) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2018-12-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2018-12-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2018-12-31..
Borrowing debt
Overview →Financial period ending 2018-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2018-12-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2018-12-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2018-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 0.00 USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 16.91M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | $16.91M | (m) |
| 2018-09-30 | (m) | (m) | $76.00K | $0.00 | (m) | (m) | $38.47M | (m) |
| 2018-06-30 | (m) | (m) | $7.78M | $0.00 | (m) | (m) | $31.97M | (m) |
| 2018-03-31 | (m) | (m) | $8.53M | $1.15M | (m) | (m) | $33.48M | (m) |
| 2017-12-31 | (m) | (m) | $8.38M | $2.61M | (m) | (m) | $33.53M | (m) |
| 2017-09-30 | (m) | (m) | $12.17M | (m) | (m) | (m) | $49.59M | (m) |
| 2017-06-30 | (m) | (m) | $13.03M | (m) | (m) | (m) | $60.55M | (m) |
| 2017-03-31 | (m) | (m) | $12.60M | (m) | (m) | (m) | $70.33M | (m) |
| 2016-12-31 | (m) | (m) | $16.40M | (m) | (m) | (m) | $65.81M | (m) |
| 2016-09-30 | (m) | (m) | $23.72M | (m) | (m) | (m) | $72.85M | (m) |
| 2016-06-30 | (m) | (m) | $23.16M | (m) | (m) | (m) | $73.78M | (m) |
| 2016-03-31 | (m) | (m) | $3.74M | (m) | (m) | (m) | $66.36M | (m) |
| 2015-12-31 | (m) | (m) | $4.74M | $0.00 | (m) | (m) | $82.14M | (m) |
| 2015-09-30 | (m) | (m) | $4.17M | $1.53M | (m) | (m) | $82.67M | (m) |
| 2015-06-30 | (m) | (m) | $4.08M | $2.55M | (m) | (m) | $101.97M | (m) |
| 2015-03-31 | (m) | (m) | $3.99M | $3.53M | (m) | (m) | $108.61M | (m) |
| 2014-12-31 | (m) | (m) | $3.91M | $4.49M | (m) | (m) | $80.49M | (m) |
| 2014-09-30 | (m) | (m) | $4.16M | $5.10M | (m) | (m) | $79.49M | (m) |
| 2014-06-30 | (m) | (m) | $4.08M | $6.00M | (m) | (m) | $80.28M | (m) |
| 2014-03-31 | (m) | (m) | $3.10M | $6.88M | (m) | (m) | $92.29M | (m) |
| 2013-12-31 | (m) | (m) | $2.15M | $7.74M | (m) | (m) | $87.98M | (m) |
| 2013-09-30 | (m) | (m) | $1.22M | $8.58M | (m) | (m) | $91.25M | (m) |
| 2013-06-30 | (m) | (m) | $301.00K | $9.40M | (m) | (m) | $62.00M | (m) |
| 2012-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | $54.99M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |